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Acetaminophen (APAP) is a widely used analgesic and antipyretic drug, but at high dose it leads to undesirable side effects, such as
hepatotoxicity and nephrotoxicity. The aim of this study was to evaluate the protective role of DDM-GSH, a mixture of L-cysteine,
L-methionine, and L-serine in a weight ratio of 2 : 1 : 1, in comparison to N-acetylcysteine (NAC), against acetaminophen- (APAP-)
induced hepatotoxicity in mice. Toxicity was induced inmice by the intraperitoneal (ip) administration of low dose (2mmol/kg) or
high dose (8mmol/kg) ofAPAP.DDM-GSH (0.4 to 1.6mmol/kg)was given ip tomice 1 h before theAPAP administration.The same
was done with NAC (0.9 to 3.6mmol/kg), the standard antidote of APAP toxicity. Mice were sacrificed 8 h after the APAP injection
to determine liver weight, serum alanine aminotransferase (ALT), and total glutathione (GSH) depletion and malondialdehyde
(MDA) accumulation in liver tissues. DDM-GSH improved mouse survival rates better than NAC against a high dose of APAP.
Moreover, DDM-GSH significantly reduced in a dose-dependent manner not only APAP-induced increases of ALT but also APAP-
induced hepatic GSH depletion and MDA accumulation. Our results suggest that DDM-GSH may be more potent than NAC in
protecting the liver from APAP-induced liver injury.
1. Introduction
Acetaminophen (APAP, 4-hydroxyacetanilide), a nonster-
oidal analgesic and antipyretic drug, is used for the treatment
of a variety of arthritic and rheumatic conditions with
musculoskeletal pain and in other painful disorders such as
headache, dysmenorrhea, myalgia, and neuralgia. It is also
indicated in conditions accompanied by generalized discom-
fort or fever, such as common cold and viral infections. APAP
is considered to be safe at the therapeutic levels. However, an
overdose of APAP in human is fairly common, being yearly in
USA the leading cause for calls to PoisonControl Centers and
accounting for more than 56,000 emergency room visits,
2,600 hospitalizations, and an estimated 458 deaths [1]. The
APAP overdose is often associated with acute liver failure [1,
2] and renal damage [3] in humans, as well as in experimental
animals.
At therapeutic doses, APAP is metabolized via glu-
curonidation and sulfuration reactions occurring primarily
in the liver and results in water-soluble metabolites that are
excreted renally. As a result of the metabolic conversion of
APAP by the microsomal CYP-450 enzyme system, a
highly reactive intermediate,N-acetyl-p-benzoquinoneimine
(NAPQI), is produced [4]. NAPQI directly reacts with glu-
tathione (GSH), and at overdoses of APAP, the depletion of
cellular GSH occurs. This allows NAPQI to bind to cellular
proteins and initiate lipid peroxidation, leading to hepatic [4]
and renal [5] injury. However, despite recognition of APAP
hepatotoxicity, therapeutic options available to either treat or
prevent its development are still limited. In the absence of
reliable and effectivemodern liver protective drugs and avail-
able traditional medicines employed for the disease treat-
ment, concerted efforts are currently channeled towards ex-
ploring complementary or alternative medicines in the dis-
ease treatment and/or prevention. Botanicals have shown
tremendous potential to serve as the alternative therapeutic
agents so as to counter the side effects of various over-the-
counter drugs [6, 7].
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DDM-GSH is a mixture of L-cysteine, L-methionine, and
L-serine in a weight ratio of 2 : 1 : 1 that we assumed to be use-
ful to optimize GSH synthesis. In fact, L-cysteine is the main
limiting step to the synthesis of glutathione [8], L-methionine
is considered to be the main amino acid involved in L-
cysteine neosynthesis in terms of SH-group donor [9, 10], and
L-serine is an important amino acid involved in L-cysteine
synthesis due to its ability to donate its carbon skeleton [11].
The current study was designed to evaluate in vivo the
protective effect of DDM-GSH, in comparison to the current
antidote N-acetylcysteine (NAC), on APAP-induced hepato-
toxicity in mice. Comparisons were made of the protective
effect of equimillimolar doses of DDM-GSH and NAC on
APAP hepatic toxicity to evaluate the potency of DDM-GSH.
2. Materials and Methods
2.1.Materials. DDM-GSHwas developed byVelleja Research
(Milan, Italy), manufactured in Procemsa Farmaceutici
(Nichelino, TO, Italy), and traded in Italy as nutritional
supplement from the group Pharmextracta/Omeopiacenza
(Pontenure, Piacenza, Italy). APAP and NACwere purchased
from Sigma-Aldrich (Milan, Italy). Detection kits for total
glutathione (GSH; no. 703002) and malondialdehyde (MDA;
no. 10009055) assays were purchased fromCaymanChemical
Company (AnnArbor,MI, USA), whereas the kits for alanine
aminotransferase (ALT; no. 17234E) and total proteins (no.
17620) determinations were purchased from Sentinel Diag-
nostics (Milan, Italy). All other chemicals were of analytical
grade.
2.2. Animals. All studies were conducted in 6- to 7-week-old
male CD-1 mice weighing 25 to 30 g, which were obtained
from Charles River Laboratories (Calco, Lecco, Italy). The
experiments were carried in accordance with the Guide for
the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH Publication no. 85-23,
revised in 1996) and approved by the local Ethical Committee.
Every effort was made to minimize animal suffering. Mice
were maintained under a controlled ambient temperature
(22 ± 1∘C), humidity (50 ± 5%), and 12 h light/dark cycles
(light on 7:00 AM to 7:00 AM). Mice were acclimated for 7
days before initiation of any procedures. Animals had free
access to water and standard rodent chow (no. 4RF25;
Mucedola S.R.L., Settimo Milanese, Milan, Italy) before
initiation of any treatment. However, mice were fasted before
treatment with APAP as indicated in the following.
2.3. APAP-Induced Mortality. In the first set of experiments,
to assess the mortality rate caused by APAP, 50 mice were
randomly divided into five experimental groups (𝑛 = 10
mice/group), including saline control group.Micewere fasted
overnight (16–18 h) prior to administration of different doses
of APAP (1 to 8mmol/kg ip) dissolved in sterile phosphate
buffered saline (PBS, pH 7.4) warmed to 40∘C. Saline control
group received sterile saline only (10mL/kg ip). All mice were
observed for up to 8 h, and lethality of APAP was taken.
2.4. NAC and DDM-GSH Treatments before Higher Dose
of APAP. In the second set of experiments, to investigate
the protective effect of NAC and DDM-GSH in the APAP-
induced mortality, 40 mice were intoxicated with the higher
dose of APAP (8mmol/kg ip). Animals were randomly
divided into the following four experimental groups (𝑛 =
10 mice/group): saline treated, APAP treated, NAC pre-
treated plus APAP, and DDM-GSH pretreated plus APAP.
Saline (10mL/kg), NAC (3.6mmol/kg) and DDM-GSH
(1.6mmol/kg)were given ip 1 h beforeAPAP.All animalswere
fasted overnight (16–18 h) prior to administration of a single
high dose of APAP. Mice were observed for up to 8 h, and
lethality of APAP was taken.
2.5. Serum ALT Assay, and Hepatic GSH and MDA Deter-
minations. In the third set of experiments, to compare
the activity of NAC and DDM-GSH, 80 mice (𝑛 = 10
mice/group) were treated with different doses of NAC (0.9
to 3.6mmol/kg ip) and DDM-GSH (0.4 to 1.60mmol/kg).
Saline (10mL/kg), NAC, and DDM-GSH were given ip 1 h
before APAP (2mmol/kg ip). All animals were fasted overn-
ight (16–18 h) prior to administration of a single dose of
APAP. At 8 h after APAP treatment, all the survived mice
were weighted and sacrificed to collect the blood from
carotis communis. Sera were separated from plasma and
stored at −20∘C until analysis. The serum levels of ALT were
measured using an enzymatic colorimetric kit according to
manufacturer’s instruction, and the results were expressed
in IU/L. Moreover, the liver was quickly excised, weighed,
divided into portions, snap frozen in liquid nitrogen, and
stored at −70∘C for biochemical analyses of total GSH and
MDA. The frozen liver slices were washed in ice-cold EDTA
solution, blotted, dissected to remove connective tissues,
weighed, and homogenized with 10% saline. Hepatic total
GSH and MDA contents were determined by Cayman’s GSH
andMDA assay kits according to manufacturer’s instruction,
and the absorbance was measured at 405 nm and 530 nm
for GSH and MDA, respectively, by Wallac 1420 VICTOR2
microplate reader (Perkin Elmer, Monza, Italy). Triplicate
assays were performed in eachmeasurement, and the average
counts were obtained from each individual sample. Proteins
in the tissues were assayed by colorimetric kit according to
manufacturer’s instruction [12]. Results were expressed in
𝜇mol GSH/mg protein and nmol MDA/mg protein.
2.6. Statistical Analysis. All values were expressed as mean ±
SE (𝑛 = 10 mice/group). The results were evaluated by one-
way analysis of variance (ANOVA) followed by a Tukey’s
multiple comparison test. The half-maximal inhibitory dose
(ED
50
) with 95% confidence limits and the dose ratio were
also calculated. Statistically significant differences between
groups were defined as 𝑃 < 0.05. All calculations were
performed with the GraphPad Prism program 5.0 (GraphPad
Software Inc., San Diego, USA).
3. Results
3.1. Effect of NAC andDDM-GSHonAPAP-InducedMortality.
When mice were treated with 1, 2, 4 and 8mmol/kg ip
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Figure 1: Dose relationship and time course of acetaminophen
(APAP-) induced mortality in mice. Saline (10mL/kg) and APAP
were given ip. 𝑛 = 10mice/group.
of APAP progressive mortality rates were observed. Particu-
larly, when the animals were intoxicated with the higher dose
of APAP (8mmol/kg ip), only a 10% of animals were survived
at 8 h (Figure 1). The survival rate at 8 h was increased to
70% and 90%, respectively, when the animals were treated
with NAC (3.6mmol/kg ip) or DDM-GSH (1.6mmol/kg ip)
administered 1 h before APAP injection (Figure 2). No death
was observed in the group treated with NAC or DDM-GSH
alone indicating that the two compounds were safe to mice
(data not shown). Considering the dosage of compounds
used, these results indicated thatDDM-GSHcould inhibit the
lethality of APAP, and this inhibition was 2-fold higher than
the one observed with NAC.
3.2. Body Weight, Liver Weight, and Mortality Rate. When
mice were treated with a low dose of APAP (2mmol/kg ip),
a 70% of animals were survived at 8 h. In these experiments,
APAP increased liver weight within 8 h compared with the
control (saline) group, whereas body weights were compara-
ble between all treatment groups (Table 1). Pretreatment of
the animals with NAC (0.9 to 3.6mmol/kg ip) or DDM-GSH
(0.4 to 1.6mmol/kg ip) significantly recovered the APAP-
induced mortality rate, and the increase of liver weight was
reduced in a dose-dependent manner (Table 1).
3.3. Serum ALT Activity. The treatment with APAP
(2mmol/kg ip) increased serumALT activity about 70-fold at
8 h (Figure 3). PretreatmentwithNAC (0.9 to 3.6mmol/kg ip)
and DDM-GSH (0.4 to 1.6mmol/kg ip) significantly pre-
vented, in a dose-dependent manner, the APAP-induced
increase inALT activity (Figure 3). Particularly, the protective
effect of DDM-GSH (ED
50
= 0.61mmol/kg ip) resulted to be
2.4-fold higher (𝑃 < 0.01) than the one obtained with NAC
(ED
50
= 1.47mmol/kg ip).
∗∗∗
###
Saline APAP  NAC 
    +
 APAP
DDM-GSH 
         +
     APAP
Su
rv
iv
al
 ra
te
s (
%
)
75
100
50
0
25
∗##
Figure 2: Mortality rate in mice 8 h after acetaminophen
(APAP, 8mmol/kg ip) administration, alone or in presence of
N-acetylcysteine (NAC; 3.6mmol/kg ip), and a mixture of L-
cysteine, L-methionine, and L-serine in ratio 2 : 1 : 1 (DDM-GSH;
1.6mmol/kg ip). Saline (10mL/kg), NAC, and DDM-GSH were
given ip 1 h before APAP. 𝑛 = 10 mice/group. ∗𝑃 < 0.05 and
∗∗∗
𝑃 < 0.001 versus saline; ##𝑃 < 0.01 and ###𝑃 < 0.001 versus
APAP.
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Figure 3: Serum alanine aminotransferase activity (ALT) in mice
8 h after acetaminophen (APAP, 2mmol/kg ip), administration,
alone or in presence of N-acetylcysteine (NAC), and a mixture of
L-cysteine, L-methionine, and L-serine in ratio 2 : 1 : 1 (DDM-GSH).
Saline (10mL/kg), NAC, and DDM-GSH were given ip 1 h before
APAP. 𝑛 = 10mice/group. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001
versus saline; #𝑃 < 0.05, ###𝑃 < 0.01, and ###𝑃 < 0.001 versusAPAP.
3.4. Total GSH and MDA Levels in the Liver. GSH plays an
important role in the detoxification of APAP [13]. As reported
in Figure 4, the hepatic GSH content of APAP (2mmol/kg
ip) group at 8 h decreased to 76.4% of the saline group (𝑃 <
0.001). BothNAC andDDM-GSH significantly recovered the
APAP-induced GSH depletion in a dose-dependent manner.
However, the protective effect obtained with DDM-GSH
(ED
50
= 0.68mmol/kg ip) was 2.2-fold higher (𝑃 < 0.01)
than that shown with NAC (ED
50
= 1.49mmol/kg ip)
(Figure 4).The hepatic MDA content, an end product of lipid
peroxidation, was increased in the APAP group (0.83 ±
0.14 nmol/mg protein) at 8 h than that in the saline group
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Table 1: Body weight, liver weight, and survival rates in mice 8 h after administration of acetaminophen (APAP, 2mmol/kg ip) alone or in
presence of N-acetylcysteine (NAC) and a mixture of L-cysteine, L-methionine, and L-serine in a ratio 2 : 1 : 1 (DDM-GSH).
Treatment Body weight (g) Liver weight (g/10 g b.w.) Survival rates (%)
Saline 23 ± 4 0.25 ± 0.01 100
APAP 24 ± 3 0.32 ± 0.01∗ 70∗
NAC 0.9mmol/kg + APAP 24 ± 3 0.30 ± 0.01∗ 90∗
NAC 1.8mmol/kg + APAP 23 ± 5 0.26 ± 0.03# 100#
NAC 3.6mmol/kg + APAP 23 ± 4 0.26 ± 0.02## 100#
DDM-GSH 0.4mmol/kg + APAP 25 ± 3 0.27 ± 0.02# 100#
DDM-GSH 0.8mmol/kg + APAP 23 ± 2 0.24 ± 0.01## 100#
DDM-GSH 1.6mmol/kg + APAP 26 ± 4 0.22 ± 0.02### 100#
Saline (10mL/kg), NAC, and DDM-GSH were given ip 1 h before APAP. Values are reported as mean ± SE (𝑛 = 10 animals/group). ∗𝑃 < 0.05 versus saline;
#
𝑃 < 0.05, ##𝑃 < 0.01, and ###𝑃 < 0.001 versus APAP.
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Figure 4: Total hepatic glutathione (GSH) in mice 8 h after
acetaminophen (APAP, 2mmol/kg ip) administration, alone or in
presence of N-acetylcysteine (NAC) and a mixture of L-cysteine,
L-methionine, and L-serine in ratio 2 : 1 : 1 (DDM-GSH). Saline
(10mL/kg), NAC, and DDM-GSH were given ip 1 h before APAP.
𝑛 = 10 mice/group. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001
versus saline; #𝑃 < 0.05, ###𝑃 < 0.01, and ###𝑃 < 0.001 versus
APAP.
(3.75 ± 0.23 nmol/mg protein) (𝑃 < 0.001). The APAP-in-
duced liver MDA increase was significantly suppressed in
both NAC and DDM-GSH pretreated groups, as compared
with APAP group, and this inhibition presented a dose-effect
relationship (Figure 5). The protective effect of DDM-GSH
(ED
50
= 0.62mmol/kg ip) resulted to be 2.6-fold higher (𝑃 <
0.01) than that obtained with NAC (ED
50
= 1.64mmol/kg
ip).
4. Discussion
APAP is the most widely used over-the-counter or prescrip-
tion painkiller in the world. APAP is metabolized in the liver
where a toxic byproduct is produced that can be removed by
conjugation with GSH. APAP overdoses, either accidental or
intentional, are the leading cause of acute liver failure in the
United States, accounting for 56,000 emergency room visits
per year [1, 14]. GSH-depletion APAP-caused seems to be
relevant not only for liver and kidney pathology, but also for
asthma induction in adults [15] and in children [16] likely
due to GSH depletion from bronchial and lung tissues. Its
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Figure 5: Hepatic lipid peroxidation (measured as malondialde-
hyde; MDA) in mice 8 h after acetaminophen (APAP, 2mmol/kg ip)
administration, alone or in presence of N-acetylcysteine (NAC), and
a mixture of L-cysteine, L-methionine and L-serine in ratio 2 : 1 : 1
(DDM-GSH). Saline (10mL/kg), NAC and DDM-GSH were given
ip 1 h before APAP. 𝑛 = 10mice/group. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01 and
∗∗∗
𝑃 < 0.001 versus saline; #𝑃 < 0.05, ###𝑃 < 0.01 and ###𝑃 < 0.001
versus APAP.
use in asthmatic subjects worsens the asthma symptoms [17].
The effect of inducing asthma seems to be provoked not only
directly in APAP user but also in newborns in case their
mothers have used acetaminophen during pregnancy [18].
In a recent past, legislation restricting pack sizes of
acetaminophen in some countries of Europe has had substan-
tial beneficial effects on mortality and morbidity associated
with self-poisoning [19], but this strategy has not been
adopted globally. The standard treatment for acetaminophen
overdose is NAC, which is given to stimulate the production
of GSH. With the aim of evaluating a possible improve-
ment in terms of liver protection, we have developed a
mixture, named DDM-GSH, of amino acids (L-cysteine, L-
methionine, and L-serine in weight ratio 2 : 1 : 1). These has
been selected on the basis of biochemical steps needed for
a proper neo-synthesis of GSH, being this last a tripeptide
constituted by Cys-Gly-Glu where the only real limiting step
is the availability of L-cysteine and being this last synthetized
from a donor of −SH (L-methionine) and a donor of the
carbon skeleton (L-serine).The idea was that, not only giving
L-cysteine (as with the usual treatment with NAC) but also
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adding two ingredients able to synthetize by their own new
L-cysteine, it would be possible to reduce further the liver
failure effect caused by APAP. Therefore, the objective of the
present study was to compare the protective effects of NAC
and DDM-GSH for APAP toxicity.The present study showed
that DDM-GSH was effective at a lower dose than NAC
when administering an equivalent millimolar dose. Also,
these results suggest that DDM-GSH is effective in reducing
APAP-induced hepatotoxicity and that DDM-GSH is likely
more effective than NAC in reducing hepatic damage in the
mouse model.
In 2001, from the page of BMJ, Law asked why a simple
strategy like to add NAC to acetaminophen tablets or sachets
for minimizing poisoning had not been enacted [20]. In all
countries, NAC is registered as a drug, and from investment
and regulatory point of view, this could be a limitation. NAC
has anyway the advantage of being less susceptible to degra-
dation in the gastrointestinal tract than L-cysteine and to
bemore readily absorbed across cell membranes.Thismolec-
ular stability likely makes NAC a better L-cysteine donor
for glutathione synthesis. L-cysteine, as well as L-methionine
and L-serine, can however be notified all over the world as a
simple dietary supplement or even used as excipient to
manufacture tablets, and this is a clear advantage of L-
cysteine versus NAC. Again, a disadvantage of L-cysteine is
linked to its possible neurotoxic effect [21]. Clear signs of
neurotoxicity were not observed at all in our investigation.
Anyway, next step will be to evaluate in organs different
from liver, that is, kidney, lung, and brain, the impact of
DDM-GSH versus NAC in terms of tissue protection, and the
evaluation of possible effects of neurotoxicity will be planned
in the same experimentation.
In conclusion, the results of our study show that likely
lower doses than NAC of these amino acids are needed in
mice to exert an evident protective liver effect. If the next
animal investigation will show the same beneficial effects also
in kidney, lung, and brain (with no neurotoxicity), we think
that at least a rationale base to start checking if this effect,
seen in mice, is observable in human too exists. If this was
confirmed, the use of L-cysteine, L-methionine, and L-serine
in formulas containing acetaminophen could reduce the risk
of liver, kidney, and bronchial pathology due to acetam-
inophen prolonged or bad use.
Disclosure
Francesco Di Pierro is the main formulator of DDM-GSH.
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